Skip to main content
ADIL
NASDAQ Life Sciences

Adial Pharma 的现金储备只够维持到 2026 年下半年，引发了对关键试验的资金担忧

feedReported by Wiseek News
Sentiment info
Negative
Importance info
8
Price
$1.93
Mkt Cap
$2.189M
52W Low
$1.88
52W High
$30.25
Market data snapshot near publication time

summarizeSummary

Adial Pharmaceuticals 提交了其年度 10-K 报告，显示其现金储备预计只能维持到 2026 年下半年。该公司报告了 798 万美元的净亏损，每股亏损 11.93 美元，与去年相比有所改善，主要是因为没有一次性支出。但是，有限的流动性是一个重大问题，因为其首要候选药物 AD04 的关键性 3 期试验的启动明确取决于获得额外的资金。这一财务约束引入了巨大的风险和不确定性，影响了其核心临床开发计划的时间表和可行性。交易者将密切关注任何有关新融资努力的公告。

在该公告发布时，ADIL的交易价格为$1.93，交易所为NASDAQ，所属行业为Life Sciences，市值约为$218.9万。 52周交易区间为$1.88至$30.25。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed ADIL - Latest Insights

ADIL
Apr 29, 2026, 9:07 AM EDT
Source: GlobeNewswire
Importance Score:
8
Adial Files New Patent Application for AD04, Targeting Market Exclusivity Through 2045
Sentiment: Positive
View Wiseek Article
ADIL
Apr 22, 2026, 9:35 AM EDT
Source: GlobeNewswire
Importance Score:
7
AD04 Manufacturing Success Paves Way for Phase 3 Clinical Batches
Sentiment: Positive
View Wiseek Article
ADIL
Apr 09, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Adial Pharmaceuticals Grants Significant Equity Awards to Executives and Directors Amidst Going Concern Doubts
Sentiment: Neutral
View Wiseek Article
ADIL
Mar 24, 2026, 9:07 AM EDT
Source: GlobeNewswire
Importance Score:
7
Bipartisan Bill to Expand Veteran Access to AUD Therapies Introduced, Benefiting Adial's AD04
Sentiment: Positive
View Wiseek Article
ADIL
Mar 06, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
8
Adial Pharmaceuticals Details Positive AD04 Regulatory Progress, Streamlined Phase 3 Path, and 2025 Financials
Sentiment: Positive
View Wiseek Article
ADIL
Mar 06, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Adial Pharmaceuticals Advances AD04 to Phase 3, Citing FDA Alignment and Potential for Single Pivotal Study
Sentiment: Positive
View Wiseek Article
ADIL
Mar 05, 2026, 5:05 PM EST
Source: Wiseek News
Importance Score:
8
Adial Pharma's Cash Runway into H2 2026 Raises Funding Concerns for Pivotal Trials
Sentiment: Negative
View Wiseek Article
ADIL
Mar 05, 2026, 5:03 PM EST
Filing Type: 10-K
Importance Score:
9
Annual Report Reveals Substantial Doubt on Going Concern, New Nasdaq Delisting Threat Looms
Sentiment: Negative
View Wiseek Article
ADIL
Mar 03, 2026, 8:17 AM EST
Filing Type: 8-K
Importance Score:
8
Adial Pharmaceuticals Secures Exclusive European Partnership Framework for AD04, Valued at Up to $60M
Sentiment: Neutral
View Wiseek Article
ADIL
Feb 24, 2026, 9:06 AM EST
Filing Type: 8-K
Importance Score:
7
Adial Pharmaceuticals Regains Nasdaq Compliance Following Reverse Stock Split
Sentiment: Positive
View Wiseek Article